VN August 2026

Vetnuus | August 2026 41 Changes in the MIC’s may explain the suboptimal clinical outcomes or the rise in antimicrobial resistance. One way around this is to increase the frequency of administration or at least apply the first drop, wait 5 minutes before applying the second drop. The second and subsequent drops provide more unbound drug. The use of serum for the treatment of serious corneal pathology and melting ulcers is well known, and both canine and equine serum can be used. There are many advantages of this product, such as the fibronectin, neuro-regeneration through NGF and VEGF factors, down-regulating proinflammatory cytokines and its antimicrobial effects. The most important is its anti-collagenolysis through the alpha-2-macroglobulin. There, however, may be some disadvantages that are worth mentioning. These include availability, no preservative, short shelf life [2 weeks refrigerated], rich in TGFB [causing corneal scarring] and rich in albumin that binds medications. Because serum [via albumin] can bind some of the drug, it would be advantageous to reduce this negative effect. This can be done in two ways: 1] The current advice is to medicate the eye with the antibiotic eye drop and then wait 5 minutes before applying a further drop of the same product or an alternative product, followed by a 15-minute wait before the serum is applied. This is then repeated 2 hrs later. The initial rapid succession of antibiotics allows any protein binding to occur with the first treatment and more bioavailability of the active drug with the second dosing. 2] The serum that is collected could be diluted to 20% serum and thus reduce the albumin content but still be effective. During ocular inflammation, there potentially can also be increased drug perfusion of systemically administered medications. It has been shown that giving a Convenia injection will result in about a 120-fold increase in the drug in the conjunctival tissue versus in healthy eyes. This effect is apparently active for 10 days. Further studies are in progress for other drug groups. Oral Famcyclovir for FHV-1 in cats can be present in the cat’s tear film at very high levels. It is important to note that studies are underway regarding oral Doxycycline. No definitive results are known regarding therapeutic levels in the tears for this drug, although it most likely will be the case. Watch this space! Other strategies can be employed to reduce the negative effect of increased albumin levels in the tear film during ocular inflammation. These can include: 1. Increase the concentration of ophthalmic formulations. This means there is more unbound drug that can achieve its biological effect. Fortified eyedrops may be needed in some cases, specifically where an antibiogram shows resistance to common eyedrops. Plumb’s Veterinary Manual describes some useful recipes. 2. Increase the frequency of administration. The second and subsequent drops provide more unbound drug. Although this is an easy concept to apply, it requires pet owner compliance and already owner non-adherence is a major issue in veterinary medicine. 3. Add products into drug formulations that show competitive inhibition to bind albumin [currently a new area of research]. 4. Stabilisation of the blood-tear-barrier. This must be done by controlling the primary ocular disease if this is possible. Currently there are no specific concepts that can be instituted to directly change the BTB. It should be obvious now that with a breakdown in the bloodtear-barrier, the leakiness of the conjunctiva not only results in increased albumin release in the tears but also allows ingress of products. Veterinarians should be very conscious of the possible negative effects of this. This may include the topical use of corticosteroid drops [eg Pred Forte] affecting diabetic patients and beta-blocker eyedrops [eg Cosopt] in congestive heart failure patients, especially small breed dogs. Multiple speakers also suggested that veterinarians need to pay more attention to client education when it comes to ocular medications. We need to be very aware that nonadherence to our intended dosing instructions is a major problem, and the frequency of dosing simply will not be done in most cases, leading to failure. We need to be proactive in demonstrating patient handling and medication techniques in the consulting room. We need to be sympathetic to owners as they may legitimately have an uncooperative patient, the eyes may be painful, or they may physically be unable to perform the requested task. In view of these problems, there is active research into new innovations in drug delivery techniques. These include maximising the routes of delivery such as episcleral, intrastromal and intracameral methods. Eye drops: There is only a 1-10% absorbance of topical eye drops [90-99% wastage]. The latter occurs due to tear turnover, nasolacrimal duct drainage and protein binding. The medication then enters the systemic circulation. It is for this reason that initial frequent dosing may be required in order to reach a steady-state therapeutic level in the eye. Many are now advocating an initial dose followed by a subsequent dose after 5 minutes and then the application of a good quality lubricant. The hyaluronic acid-based products are best. The rationale for this is that the subsequent drop is able to bind to the complex longer chain molecules of the lubricant and provide a longer contact time and more efficient drug release. Even pre- treating with hyaluronic acid drops can increase drug retention by 1.8-fold and 2.0-fold if X-linked HA is used. The conjunctival and episcleral routes: A subconjunctival injection provides a high concentration of medication to the front part of the eye. Only to be used when there is no topical formulation. This may include triamcinolone, amphotericin B, cephalosporins and mesenchymal stem cells. This type of injection may only last 12-24 hours. Non-depot type drugs rapidly drain directly into the systemic circulation. Sustained delivery systems [silicone implants] include subconjunctival implants of cyclosporine, tacrolimus, Bromfenac, brinzolamide, and other medications. Intracorneal injection: These include injection techniques with 27-31G needles and use of microneedles [600um] delivering an injection directly into the stroma of the cornea. This can be used for Amphotericin B and Voriconazole medication of equine stromal abscesses. Regulars I Ophthalmology Column >>>42

RkJQdWJsaXNoZXIy OTc5MDU=